PHAXIAM THERAPEUTICS financials
PHAXIAM THERAPEUTICS
Country: FR Reporting currency: EUR Latest annual report: 2023-12-31
LEI:
969500U8ZZCODU8A9374 Financial statements
(EUR, as reported — unscaled; 91 line items across 3 annual periods)
| Line item | 2023 | 2022 | 2021 |
|---|---|---|---|
| Income statement | |||
| Other income | €1.3M | €31.0M | €4.2M |
| Operating expenses | €25.0M | €33.8M | €60.7M |
| Operating profit (EBIT) | -€23.7M | -€2.8M | -€56.5M |
| Net finance income / (cost) | -€37.0K | €3.1M | €2.7M |
| Finance costs | €511.0K | €1.4M | €2.7M |
| Income tax expense | -€208.0K | €521.0K | €2.0K |
| Profit for the year | -€23.5M | -€228.0K | -€53.8M |
| Total comprehensive income | -€23.7M | €194.0K | -€54.3M |
| Per share | |||
| Basic EPS | €-5.00 | €-0.07 | €-22.71 |
| Diluted EPS | €-5.00 | €-0.07 | €-22.71 |
| Free cash flow / share | €-5.25 | €-9.78 | €-24.09 |
| Cash flow statement | |||
| Net cash from operating activities | -€24.4M | -€31.8M | -€56.8M |
| Net cash from investing activities | €171.0K | €38.1M | -€345.0K |
| Purchase of PP&E (capex) | €217.0K | €85.0K | €298.0K |
| Purchase of intangibles | €0 | €0 | €0 |
| Net cash from financing activities | -€3.7M | -€1.8M | €44.7M |
| Proceeds from borrowings | €0 | €3.1M | €12.2M |
| Repayments of borrowings | €2.7M | €3.1M | €0 |
| Lease liability payments | €1.1M | €1.5M | €1.7M |
| Balance sheet | |||
| Total assets | €51.3M | €45.8M | €66.8M |
| Non-current assets | €35.1M | €3.2M | €26.7M |
| Property, plant & equipment | €1.0M | €393.0K | €19.0M |
| Right-of-use assets | €2.9M | €2.6M | €6.9M |
| Intangible assets & goodwill | €9.6M | €0 | €0 |
| Current assets | €16.2M | €42.6M | €40.0M |
| Inventories | €0 | €0 | €0 |
| Trade & other receivables | €103.0K | €76.0K | €12.0K |
| Cash & equivalents | €10.5M | €38.8M | €33.7M |
| — attributable to owners | €25.6M | €23.5M | €22.8M |
| Non-current liabilities | €10.4M | €10.6M | €23.9M |
| Long-term borrowings | €7.0M | €7.5M | €15.2M |
| Lease liabilities (non-current) | €2.3M | €2.7M | €8.2M |
| Current liabilities | €15.3M | €11.7M | €20.0M |
| Lease liabilities (current) | €718.0K | €775.0K | €1.8M |
| Trade & other payables | €7.1M | €5.1M | €14.2M |
| Deferred tax liabilities | €0 | €0 | €0 |
| Derived metrics | |||
| Free cash flow | -€24.6M | -€31.8M | -€57.1M |
| Return on equity | -91.7% | -1.0% | -235.5% |
| Cash conversion ratio | 1.04× | 139.31× | 1.06× |
| Capex coverage | -112.57× | -373.68× | -190.50× |
| Other reported items | |||
| Adjustments For Decrease Increase In Inventories | €0 | €0 | €0 |
| Adjustments For Decrease Increase In Other Current Assets | -€923.0K | €2.7M | -€94.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | €218.0K | -€63.0K | -€8.0K |
| Adjustments For Depreciation and Amortisation Expense | €793.0K | €4.6M | €5.4M |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | €0 | €0 | €1.2M |
| Adjustments For Income Tax Expense | -€208.0K | €521.0K | €2.0K |
| Adjustments For Increase Decrease In Other Current Liabilities | -€152.0K | -€1.5M | -€574.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€1.2M | -€9.2M | -€6.5M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €112.0K | -€23.9M | €17.0K |
| Adjustments For Provisions | -€8.0K | €445.0K | €135.0K |
| Adjustments For Sharebased Payments | €693.0K | €447.0K | €1.3M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | €111.0K | -€510.0K | -€3.6M |
| Cash and Cash Equivalents In Subsidiary Or Businesses Acquired Or Disposed2013 | €10.0K | — | — |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€22.1M | -€23.7M | -€49.6M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | -€10.0K | €0 | €0 |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €3.2M | €2.6M | €164.0K |
| Current Derivative Financial Liabilities | €0 | €0 | €0 |
| Current Provisions | €96.0K | €314.0K | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€342.0K | €495.0K | €1.7M |
| Equity and Liabilities | €51.3M | €45.8M | €66.8M |
| Finance Income | €474.0K | €4.5M | €5.4M |
| General and Administrative Expense | €14.1M | €13.9M | €15.6M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | €0 | €0 | €0 |
| Income Taxes Paid Refund Classified As Operating Activities | €294.0K | €3.0K | €2.0K |
| Increase Decrease In Cash and Cash Equivalents | -€28.3M | €5.1M | -€10.7M |
| Increase Decrease In Working Capital | €2.1M | €8.1M | €7.2M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €693.0K | €447.0K | €1.3M |
| Increase Decrease Through Transfers and Other Changes Equity | €7.0K | — | €195.0K |
| Intangible Assets Other Than Goodwill | €21.4M | €5.0K | €15.0K |
| Issued Capital | €6.1M | €3.1M | €3.1M |
| Noncurrent Derivative Financial Liabilities | €0 | €0 | €0 |
| Noncurrent Provisions | €1.1M | €419.0K | €524.0K |
| Other Comprehensive Income | -€164.0K | €422.0K | -€460.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €49.0K | €235.0K | €68.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€213.0K | €187.0K | -€528.0K |
| Other Current Assets | €5.6M | €3.8M | €6.3M |
| Other Current Liabilities | €4.2M | €2.9M | €3.9M |
| Other Noncurrent Assets | €205.0K | €195.0K | €876.0K |
| Proceeds From Issuing Other Equity Instruments | €0 | €0 | €0 |
| Proceeds From Issuing Shares | €0 | €0 | €34.6M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €23.0K | €37.6M | €0 |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €360.0K | €586.0K | €145.0K |
| Purchase of Financial Instruments Classified As Investing Activities | €4.0K | €5.0K | €192.0K |
| Research and Development Expense | €10.9M | €19.9M | €45.1M |
| Reserve of Exchange Differences On Translation | €1.2M | €1.4M | €1.2M |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€7.8M | -€29.8M | -€25.3M |
| Retained Earnings Profit Loss For Reporting Period | -€23.5M | -€228.0K | -€53.8M |
| Revenue and Operating Income | €1.3M | €31.0M | €4.2M |
| Share Issue Related Cost | — | — | €3.8M |
| Share Premium | €49.7M | €49.0M | €97.6M |
Methodology
Every line item above is a fact tagged in PHAXIAM THERAPEUTICS's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.